Skip to main content
. Author manuscript; available in PMC: 2021 Nov 22.
Published in final edited form as: Pain Med. 2020 Feb 1;21(2):308–316. doi: 10.1093/pm/pnz038

Table 1.

Frequency of policy characteristics

States, Number (%) N=22 Policies, Number (%) N=31
Type of Policy
Guideline 13 (59%) 15 (48%)
Rule/Regulation 4 (18%) 4 (13%)
Prior Authorization 4 (18%) 4 (13%)
Legislative Act 3 (14%) 4 (13%)
Claim Denial 2 (9%) 2 (6%)
Alert System/Automatic Patient Report 2 (9%) 2 (6%)
Sponsoring Organization
Medical Board 9 (41%) 9 (29%)
Medicaid 6 (27%) 7 (23%)
Workers’ Compensation 5 (23%) 6 (19%)
Health Department 5 (23%) 5 (16%)
State Legislature 3 (14%) 4 (13%)
Pharmacy Board 2 (9%) 2 (6%)
Prescription Drug Monitoring Program 2 (9%) 2 (6%)
Threshold Level
30 2 (9%) 2 (6%)
50 1 (5%) 1 (3%)
60 1 (5%) 1 (3%)
80 3 (14%) 4 (13%)
90 4 (18%) 4 (13%)
100 5 (23%) 5 (16%)
120 10 (45%) 11 (35%)
300 2 (9%) 2 (6%)
Patient exclusions
Terminal/hospice/palliative care patients 12 (55%) 14 (45%)
Acute/etiologic pain 10 (45%) 10 (32%)
Cancer/malignant pain 8 (36%) 11 (35%)
Long-term care facility/nursing home patients 5 (23%) 5 (16%)
Emergency Room care patients 2 (9%) 2 (6%)
Other patient groups 3 (14%) 3 (10%)
No patient groups excluded 7 (32%) 7 (23%)
Short courses of opioids excluded 5 (23%) 5 (16%)
Excluded circumstances
Specialist consulted 14 (64%) 15 (48%)
Pain contract/patient education 7 (32%) 7 (23%)
Evidence of tapering 4 (18%) 4 (13%)
Clinical judgment 6 (27%) 7 (23%)
Improved pain or function 5 (23%) 5 (16%)
Prescription Drug Monitoring Program checked 4 (18%) 4 (18%)
Drug testing 3 (14%) 3 (10%)
Other circumstances specified 3 (14%) 3 (10%)
No circumstances specified 9 (41%) 10 (32%)